# Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

> **NCT05083364** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- C3 Glomerulopathy
- IgA Nephropathy

## Interventions

- **DRUG:** ARO-C3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05083364
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-01
- **Primary completion:** 2025-05-05
- **Final completion:** 2025-10-31
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083364, "Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05083364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*